Abstract
Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Melanoma,Hodgkin Disease,Carcinoma, Non-Small-Cell Lung, Date of authorisation: 17/07/2015, Revision: 21, Status: Authorised
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
